$16.81
Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
Theravance Biopharma Insider Sold Shares Worth $5,791,555, According to a Recent SEC Filing
Theravance Stock Down 3% After Zymeworks Announces Buyout
Zymeworks agrees to buy Theravance Biopharma for $929m
Overview
52-week range
$10
$21
60% of range
Avg surprise (last 3)
+176.0%
Avg reaction (last 2)
-0.2%
50% positive
Latest IV / EM
135%
EM ±30.9% · $18 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.06 | $-0.06 | 0.0% | +77.8% | +0.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.07 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $1.08 | $-0.25 | +532.0% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.27 | $-0.26 | -3.9% | — | -0.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.26 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.34 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.24 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.17 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.28 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | $0.14 | $1.08 | -87.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-9M | — | $-6M | $-3M | $-14M | — | $-11M | $-16M |
| Net income | $-5M | — | $4M | $55M | $-14M | — | $-13M | $-17M |
| EPS (diluted) | $-0.10 | — | $0.07 | $1.08 | $-0.27 | — | $-0.26 | $-0.34 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $288M | $168M | $175M | $282M | $111M | $38M | $23M | $46M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $418M | $418M | $355M | $366M | $150M | $161M | $116M | $119M |
| Total assets | $472M | $486M | $415M | $426M | $344M | $354M | $356M | $362M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $291M | $297M | $233M | $225M | $166M | $176M | $186M | $194M |